USA flag logo/image

An Official Website of the United States Government

Company Information:

Name: CBR LABORATORIES, INC.
Address: 800 HUNTINGTON AVE
BOSTON, MA 02115
Located in HUBZone: No
Woman-Owned: No
Minority-Owned: No
URL: N/A
Phone: (617) 278-3356

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,177,107.00 17
SBIR Phase II $1,138,246.00 2

Award List:

SPECIFIC AIMS: WE HAVE RAISED A POTENT MONOCLONAL ANTIBODY (RBC-A) AGAINST BLOOD GROUP A ANTIGEN.

Award Year / Program / Phase: 1985 / SBIR / Phase I
Agency: HHS
Principal Investigator: Beverly pohl , PRINCIPAL INVESTIGATOR
Award Amount: $50,000.00
Abstract:
Specific aims: we have raised a potent monoclonal antibody (rbc-a) against blood group a antigen. our aims are to: 1. raise additional monoclonal antibodies to red blood cell alloantigens; 2. institute the technology for the production of human 3. complete the study on the commercial value of our… More

BLOOD BANK IMMUNODIAGNOSTICS FOR PLATELET PROTEINS

Award Year / Program / Phase: 1987 / SBIR / Phase I
Agency: HHS
Principal Investigator: David h bing phd
Award Amount: $50,000.00
Abstract:
During the next year, over 4 million units of platelets will be transfused in the united states for a variety of medical reasons. in spite of the remarkable body of knowledge about platelet physiology and biochemistry, efficacy of this blood product in correcting bleeding problems is usually… More

PURE FACTOR IX FOR TREATMENT OF HEMOPHILIA B

Award Year / Program / Phase: 1987 / SBIR / Phase I
Agency: HHS
Principal Investigator: David h bing phd
Award Amount: $50,000.00
Abstract:
Hemophilia b is a severe bleeding disorder characterized by a functional deficiency in the blood coagulation protein factor ix (or christmas factor). therapy for bleeding episodes in these patients requires the intravenous replacement of factor ix given as fresh frozen plasma or with commercially… More

NOVEL HLA-LINKED DNA IN A YEAST ARTIFICIAL CHROMOSOME

Award Year / Program / Phase: 1988 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $50,000.00
Abstract:
Although a large number of dna clones exist which cover manyof the genes of the human major histocompatibility complex (mhc), a number of large gaps exist, including the 275-300 kb region of dna between human leucocyte antigen (hla)-dr and the complement genes. the mhc encodes genes determing… More

ASSAYS FOR HEPATITIS B VIRUS WITH HUMAN LEUKEMIC CELL LINES

Award Year / Program / Phase: 1988 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $50,000.00
Abstract:
Infection of humans with the small hepatotrophic dna virus, hepatitis b virus (hbv), can lead to acute or chronic hepatitis, cirrhosis and primary hepatocellular carcinoma. in spite of advances in testing of blood and the recent introduction of a safe effective vaccine, there is still an incidence… More

IMMUNODIAGNOSTIC FOR MEASURING HUMAN CELL PROLIFERATION

Award Year / Program / Phase: 1989 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $50,000.00
Abstract:
The evaluation of tissues for the presence of cancer cells in abnormal tissues is an important and crucial step in the diagnosis, disease management, and control of cancer. cbr laboratories, inc., has generated a mouse monoclonal antibody that detects a glycolipid antigen (paa) on proliferating t… More

SIMPLIFIED FORZEN-BLOO

Award Year / Program / Phase: 1989 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $50,000.00

A NEW MARKER FOR RETROVIRUS-INFECTED LYMPHOCYTES

Award Year / Program / Phase: 1990 / SBIR / Phase I
Agency: HHS
Principal Investigator: David H Bing
Award Amount: $50,000.00
Abstract:
The long-term objective is to develop reagents that will indicate the extent of, or may intervene in, the transformation of human lymphocytes infected by retroviruses. this study is based on recent findings that human t-cell lines normally express a 5.5-kb mrna that codesfor the mitogenic form of… More

SIMPLIFIED FORZEN-BLOO

Award Year / Program / Phase: 1991 / SBIR / Phase II
Agency: HHS
Principal Investigator:
Award Amount: $388,246.00
Abstract:
The overall goal of this project is to determine whether frozen red blood cells stored at -25 degrees centigrade for periods up to 6 months will have an in vivo survival equal to that of frozen red blood cells stored at -65 degrees centigrade for periods up to 10 years and whether they will meet the… More

Image Processing in Prenatal Analysis

Award Year / Program / Phase: 1993 / SBIR / Phase I
Agency: HHS
Principal Investigator: David H. Bing
Award Amount: $50,000.00
Abstract:
For prenatal cytogenetic analysis, cells are now sampled from the amniotic sac, a procedure which carries some risk and some women will not submit to it. There is a desire to find a less invasive and less risky sampling procedure. A number of laboratories are developing procedures to enrich fetal… More

Generation Of Recombinant Human Elastase Inhibitor (HEI)

Award Year / Program / Phase: 1993 / SBIR / Phase I
Agency: HHS
Principal Investigator: Takashi Sugimori
Award Amount: $50,000.00
Abstract:
We will use a recombinant technique to produce Human Elastase Inhibitor (HEI); therefore, its potential as anti-inflammatory pharmaceutical agent can be evaluated. The known properties of HEI, one of very few naturally occurring human inhibitors of elastase, indicate that it will likely serve as… More

Preclinical Study of Recombinant Elastase Inhibitor

Award Year / Program / Phase: 1993 / SBIR / Phase I
Agency: HHS
Principal Investigator: David H. Bing
Award Amount: $50,000.00

Preclinical Study of Recombinant Elastase Inhibitor

Award Year / Program / Phase: 1995 / SBIR / Phase II
Agency: HHS
Principal Investigator: David H. Bing
Award Amount: $750,000.00
Abstract:
The long term goal is to define the biochemical and immunological characteristics of a vaccine delivery system that will be stable to both environmental and biological effects, thus, allowing for sustained and prolonged release of immunogens, maximal stimulation of the immune system, and protective… More

Bridge Amplification for Blood Banking Tests

Award Year / Program / Phase: 1995 / SBIR / Phase I
Agency: HHS
Principal Investigator: David Bing
Award Amount: $79,376.00
Abstract:
The long term objective of this project is to develop a novel diagnostic testing methodology that csafety and volume of the blood supply. The basis for this method is an innovative amplification techBRIDGE allows for the simultaneous detection of a plurality of organisms or cellular antigens in a… More

Novel Inhibitor of Hageman Factor

Award Year / Program / Phase: 1995 / SBIR / Phase I
Agency: HHS
Principal Investigator: David Bing
Award Amount: $77,818.00
Abstract:
We will investigate the ability of a novel human endothelial cell derived protein to ameliorate advbiomaterials in contact with blood. This protein (HEDA) has recently been purified from human endothand has been found to inhibit activation of Hageman factor (factor XII) by glass. Factor XII… More

PEPTIDE INHIBITORS OF NFAT ACTIVATION BY CALCINEURIN

Award Year / Program / Phase: 1998 / SBIR / Phase I
Agency: HHS
Principal Investigator: Hogan, Patrick G
Award Amount: $99,997.00

RM/NEI DRY POWDER INHALATION THERAPY FOR CYSTIC FIBROSIS

Award Year / Program / Phase: 1999 / SBIR / Phase I
Agency: HHS
Principal Investigator: Dianne M. Kenney
Award Amount: $115,388.00
Abstract:
Not Available Micro Oscillator Inc. (MOI) proposes to develop a low operating power (drawing less than 1 mA) timer base capable of maintaining high frequency accuracy at shock loads up to 100,000 G. The timer base will use a circuits based on a patented CMOS I.C clock oscillator developed by MOI… More

N/A

Award Year / Program / Phase: 2000 / SBIR / Phase I
Agency: HHS
Principal Investigator: Robert J. Mandle
Award Amount: $137,094.00

N/A

Award Year / Program / Phase: 2000 / SBIR / Phase I
Agency: HHS
Principal Investigator: Dianne M. Kenney
Award Amount: $117,434.00
Abstract:
Not Available There is a critical and growing need to achieve better mission designs and hardware, with fewer resources, in less time. Tools, such as the Millennia engine, developed by the Network Engineering Section of Information Systems Development, headed by Norman